- Trials with a EudraCT protocol (1,480)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (24)
1,480 result(s) found for: Depression.
Displaying page 12 of 74.
| EudraCT Number: 2020-005162-33 | Sponsor Protocol Number: RF-2018-12365308 | Start Date*: 2022-11-08 | |||||||||||
| Sponsor Name:IRCCS CENTRO SAN GIOVANNI DI DIO - FATEBENEFRATELLI AFFERENTE ALLA PROVINCIA LOMBARDO VENETA ORDINE OSPEDALIERO DI SAN G | |||||||||||||
| Full Title: Targeting inflammation in depression using minocycline: a patient stratification approach using peripheral inflammatory biomarkers, PET and MRI | |||||||||||||
| Medical condition: depressed patients with high levels of inflammation (crp>2 mg/l) and non responder to at least two different antidepressants | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-003109-92 | Sponsor Protocol Number: CRFSPN004 | Start Date*: 2020-03-20 |
| Sponsor Name:Trinity College Dublin | ||
| Full Title: Ketamine as an adjunctive therapy for Major Depression (2) - a randomised controlled trial | ||
| Medical condition: Major Depression | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-002947-27 | Sponsor Protocol Number: SIMCODE | Start Date*: 2020-01-22 |
| Sponsor Name:Charité – Universitätsmedizin Berlin | ||
| Full Title: Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial | ||
| Medical condition: Patients with comorbid obesity (body mass index ≥ 30) and major depression | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2024-000604-29 | Sponsor Protocol Number: VENL-CAZ-3001 | Start Date*: 2026-03-17 | |||||||||||
| Sponsor Name:Viatris Pharmaceutical Japan GK | |||||||||||||
| Full Title: A placebo-controlled, randomized, double-blind, multicenter study to evaluate the efficacy and safety of venlafaxine in Japanese pediatric outpatients with Major Depressive Disorder (MDD) or Persis... | |||||||||||||
| Medical condition: Major Depressive Disorder (MDD) or Persistent Depressive Disorder (PDD) | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2024-000605-33 | Sponsor Protocol Number: VENL-CAZ-3002 | Start Date*: 2026-03-17 | |||||||||||
| Sponsor Name:Viatris Pharmaceutical Japan GK | |||||||||||||
| Full Title: An open-label, long-term extension, multicenter study to evaluate the safety and efficacy of venlafaxine in Japanese pediatric outpatients with Major Depressive Disorder (MDD) or Persistent Depress... | |||||||||||||
| Medical condition: Major Depressive Disorder (MDD) or Persistent Depressive Disorder (PDD) | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-003251-13 | Sponsor Protocol Number: D1449L00002 | Start Date*: 2005-10-20 |
| Sponsor Name:AstraZeneca UK Ltd | ||
| Full Title: Quetiapine Augmentation In Treatment-Resistant Depression – An Open Pilot Study | ||
| Medical condition: Depression | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-003992-23 | Sponsor Protocol Number: 54135419SUI3002 | Start Date*: 2017-07-26 | ||||||||||||||||||||||||||
| Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||||||||||||
| Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Sympto... | ||||||||||||||||||||||||||||
| Medical condition: Major Depressive Disorder with Imminent Risk of Suicide | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: BE (Completed) PL (Completed) CZ (Completed) AT (Completed) LT (Completed) FR (Completed) ES (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2016-002326-36 | Sponsor Protocol Number: 2016-858 | Start Date*: 2016-11-09 | ||||||||||||||||
| Sponsor Name:Region Hovedstadens psykiatriske hospital | ||||||||||||||||||
| Full Title: Effects of erythropoietin (EPO) on cognitive side-effects of electroconvulsive therapy (ECT) (EPO-T) | ||||||||||||||||||
| Medical condition: Unipolar/bipolar depression | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2021-005992-38 | Sponsor Protocol Number: CMIJ821B12201 | Start Date*: 2022-10-26 | |||||||||||
| Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, tolerability, and pharmacokinetics of single subcutaneous MIJ821 injection in addition to stan... | |||||||||||||
| Medical condition: Treatment Resistant Depression | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-002769-37 | Sponsor Protocol Number: DR190058 | Start Date*: 2019-11-13 |
| Sponsor Name:CHRU DE TOURS | ||
| Full Title: Cerebrovascular reaction to nitrous oxide in Resistant Depression: Pilot study (PROTO-BRAIN) | ||
| Medical condition: Resistant Depression - Nervous Breakdown | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-002020-37 | Sponsor Protocol Number: 20/15 | Start Date*: 2015-09-03 | |||||||||||
| Sponsor Name:St Patrick's Mental Health Services | |||||||||||||
| Full Title: Ketamine for relapse prevention in recurrent depressive disorder: a randomised, controlled pilot trial | |||||||||||||
| Medical condition: Recurrent depressive disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-003190-29 | Sponsor Protocol Number: HMNC-101 | Start Date*: 2012-01-30 | |||||||||||||||||||||
| Sponsor Name:HolsboerMaschmeyer NeuroChemie (HMNC) GmbH | |||||||||||||||||||||||
| Full Title: Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication according to the the ABCB1 Gene | |||||||||||||||||||||||
| Medical condition: - Major Depression, single or recurrent, without psychotic features - Bipolar Disorders, currently depressed, without psychotic features | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2018-003573-97 | Sponsor Protocol Number: PSIDER | Start Date*: 2020-08-27 | |||||||||||
| Sponsor Name:King's College London [...] | |||||||||||||
| Full Title: A randomised, placebo controlled trial of psilocybin in treatment resistant depression: A feasibility study | |||||||||||||
| Medical condition: Major depressive disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-020956-69 | Sponsor Protocol Number: OX02 | Start Date*: 2011-02-23 | ||||||||||||||||
| Sponsor Name:Universitätsklinikum Freiburg | ||||||||||||||||||
| Full Title: Effekte von Oxytocin bei Patientinnen und Patienten mit Borderline-Persönlichkeitsstörung | ||||||||||||||||||
| Medical condition: ICD-10 F60.3 Emotionally unstable personality disorder Two types may be distinguished: the impulsive type, characterized by emotional instability and lack of impulse control, and the borderline typ... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2022-000034-42 | Sponsor Protocol Number: 2022-001 | Start Date*: 2022-04-22 | ||||||||||||||||
| Sponsor Name:Aarhus University Hospital - Psychiatry, Department of Affective Disorders | ||||||||||||||||||
| Full Title: The Estimated 12-Hour Serum Lithium Level Pilot Study | ||||||||||||||||||
| Medical condition: Bipolar disorder Unipolar Depression | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-001580-11 | Sponsor Protocol Number: LuAA21004_305 | Start Date*: 2009-04-09 | |||||||||||
| Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | |||||||||||||
| Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder | |||||||||||||
| Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) DE (Completed) NL (Completed) LV (Completed) LT (Completed) FR (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004586-24 | Sponsor Protocol Number: ESKETINTRD3003 | Start Date*: 2015-09-22 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression | |||||||||||||
| Medical condition: Treatment-resistant Major Depression | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) PL (Completed) ES (Completed) HU (Completed) CZ (Completed) SK (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-002757-26 | Sponsor Protocol Number: BH-200-03 | Start Date*: 2023-03-28 | |||||||||||
| Sponsor Name:HMNC Holding GmbH | |||||||||||||
| Full Title: A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) i... | |||||||||||||
| Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LT (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) DE (Ongoing) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-004349-42 | Sponsor Protocol Number: NP27936 | Start Date*: 2012-07-16 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
| Full Title: A randomized, double-blind, 12- week, parallel group, placebo-controlled study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome. | |||||||||||||
| Medical condition: Fragile X Syndrome (FXS) | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) SE (Completed) ES (Completed) | |||||||||||||
| Trial results: Removed from public view | |||||||||||||
| EudraCT Number: 2007-003159-36 | Sponsor Protocol Number: EFC10290 | Start Date*: 2007-10-24 | |||||||||||
| Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
| Full Title: An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patient... | |||||||||||||
| Medical condition: Treatment of Major depressive disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) FI (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.